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The clinical application of new genetic technologies will be and already is of great beneﬁt to children
with unexplained developmental disabilities or congenital anomalies. In most cases, it will be their
parents who, together with medical professionals, make decisions about what should be disclosed and
how the information will be used. We conducted eight exploratory focus group discussions with
stakeholders to provide a broad sketch of concerns and ideas around the communication of results from
next-generation sequencing technologies involving children. Stakeholders included those with (grand-)
children of various ages and those without children; those involved professionally with genetics and
those who were not; and a range of ages. Participants were asked to focus on which secondary variants
they would and would not want disclosed about their (hypothetical) children or themselves. While the
literature often concentrates on the medical and scientiﬁc characteristics of secondary variants, focus
group participants were also interested in factors involving the parent-child relationship and the broader
context. This resulted in more ﬂexibility surrounding the types of secondary variants disclosed to parents
than much of the literature currently supports. In addition, participants would on occasion use the same
factors to argue opposing positions. The “Family Illness Paradigms model” can help explain this seeming
contradiction. This model emphasises the importance of how the family reacts to personal and family
experiences of disease and loss, more than the fact of having these experiences.
 2015 Published by Elsevier Masson SAS.94
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1121. Introduction
Thanks to rapidly falling costs, the widespread clinical imple-
mentation of whole genome and exome sequencing (WGS and
WES, respectively) is imminent [Hayden, 2014]. Some are already
using WGS and WES in clinical diagnosis [Choi et al., 2009;
Lupski et al., 2010; Worthey et al., 2011]. However, as has often
been noted, reports of falling sequencing costs regularly lose sight
of invariably high analysis and follow-up costs [Mardis, 2010].
One of the potential causes of high analysis and follow-up costs
is the phenomenon of so-called secondary variants or incidental
ﬁndings. Secondary variants introduce costs at various levels:
longer pre-test counselling and informed consent discussions;
conﬁrmation of analytical and clinical validity and clinical utility;
potential post-test discussions with colleagues, Institutional Re-
view Boards or their equivalents, and patients or researchics and Law, Kapucijnenvoer
: þ32 16 33 69 52.
ven.be (G.M. Christenhusz).
.
113
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116
husz GM, et al., Focus group
enetics (2015), http://dx.doiparticipants; plus follow-up costs in primary healthcare. A key step
in the development of standard discussion protocols, informed
consent procedures, and panels or ﬁlters is the investigation of
which secondary variants various stakeholders deem worthy of
identifying and disclosing and on what basis.
As in a previous study [Christenhusz et al., 2014], we focus here
on the particular issue of the disclosure of secondary variants to
parents. A qualitative research method was chosen. This allows
the emergence of new themes that are relevant to the research
participants, a vital step when investigating a new topic. The
question of disclosure to parents was focussed on, as it is children
with heritable diseases who will be and already are a key
beneﬁciary of the clinical application of new genetic technologies
[Boycott et al., 2014]. In most cases, it will be these children’s
parents who, together with medical professionals, make decisions
about what should be disclosed and how the information will be
used. Only one ofﬁcial guideline has been published to date on
the issue of secondary variants arising from genetic testing, that
of the American College of Medical Genetics and Genomics
(ACMG) in April 2013 (with revisions published in a press release117
118
119
discussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
Table 1
Socio-demographic characteristics of the focus group participants and their children. Note that some participants expressed familiarity with genetic diseases in more than
category (family history, studies, or work), so that the numbers in the ﬁnal column exceed the number of participants.
Focus group Reason for recruiting this
particular group
Recruitment strategy Number and
gender of
participants
Age
range
Children per participant Familiarity with
genetic diseases
Number of contact people and
group composition
Nearest
5 years
Median number and age range Number through
family history,
studies, or work
Parents of young
children
Parents with children of a
certain age; not involved with
genetics professionally
2 contact people delegated; 2
acquaintance groups
4 women,
2 men
26e45 3 children (under 5 years of age,
primary school age)
2 family history;
3 through studies;
2 through work;
2 no familiarity
Parents of
teenagers and
young adults
Parents with children of a
certain age; not involved with
genetics professionally
2 contact people delegated; 2
acquaintance groups þ 1
stranger
3 women,
3 men
36e55 2e3 children (teenagers, over
18 years of age still at home and
left home)
5 family history;
1 through studies;
1 through work;
1 no familiarity
Immigrant parents
(5 Asian, 1
Middle Eastern,
1 East European)
Parents with a non-Belgian
ethnic background; not
involved with genetics
professionally
Integration ofﬁce of the
province of Flemish-Brabant;
strangers þ 1 married couple
4 women,
3 men
26e45 2 children (under 5 years of age,
primary school age, teenager)
4 family history;
1 through studies;
3 no familiarity
Clinical genetics
centre staff
Parents and involved with
genetics professionally
1 staff member delegated 4 women,
1 man
36e55 2 children (all ages) 1 family history;
all through studies;
all through work
Bio-informaticians Involved with genetics
professionally
1 staff member delegated 7 men 26e55 4 participants with no children;
3 participants with a mean of 2
children (all ages)
4 family history;
6 through studies;
6 through work
Biological sciences
master students
Not parents; younger than
other groups; familiar with
medicine and genetics through
studies
3 masters classes approached 4 women,
2 men
18e25 0 children 3 family history;
6 through studies;
4 through work
Genetics PhD
students
Not parents; involved with
genetics professionally
Fellow PhD students 4 women,
3 men
18e45 0 children 3 family history;
6 through studies;
6 through work;
1 no familiarity
Grandparents Asked to focus on their
grandchildren; older than other
groups; not involved with
genetics professionally
2 contact people delegated; 2
sets of siblings and 2 strangers
4 women,
2 men
46e75 4 grandchildren (under 5 years
of age, primary school age), 2
adult children
2 family history;
1 through studies;
3 no familiarity
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EJMG3016_proof ■ 3 February 2015 ■ 2/9on 1 April 2014) [Green et al., 2013]. Other guidelines are currently
being drafted. The ACMG guideline recommends that a list of
secondary variants (conﬁrmed mutations associated with serious
conditions judged to have clinical utility) be checked every time
WGS or WES is conducted in a clinical setting, regardless of the
patient’s age. This appears to contradict existing guidelines
prohibiting the genetic testing of children for adult-onset condi-
tions [Borry et al., 2009; Clayton et al., 2014]. The ACMG justiﬁed
the policy change by arguing that secondary variants are
qualitatively different to primary genetic test results, because
disclosure of secondary variants can provide signiﬁcant
information to the child-patient’s family (speciﬁcally, the child-
patient’s parents) that would not be known otherwise [Evans,
2013]. One of the aims of the present study was to investigate
whether the time of onset of a genetic condition is considered to
be a relevant factor to parents in secondary variant disclosure
discussions, and thus indirectly investigate whether participants
support previous or emerging guidelines.
In contrast to other published qualitative studies, we did not
divide our focus groups according to medical professionals and lay
people. Previous research by Lemke et al. suggests that clinical
genetics professionals may be more conservative in their disclosure
recommendations for parents of patients compared to what they
would like disclosed about their own child [Lemke et al., 2013]. In
the present study, we wished to concentrate on the respondents
as parents (or hypothetical parents), not as medical experts.
Furthermore, all focus group participants were instructed to
respond as realistically as possible, and the moderator
occasionally reminded participants that the researchers were not
interested in what the participants thought parents in general
should or should not do, but in how the participants thoughtPlease cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doithey themselves would act in a given situation. Responses based
on personal experience and what was judged to be personally
meaningful were encouraged over hypothetical views [Rabiee,
2004]. In the current study, all responses about secondary variant
disclosure were of course unavoidably hypothetical as none of the
participants had direct experience with receiving secondary
variants regarding themselves or their children. In addition, the
two student groups could only respond as hypothetical parents.
To offset this, participants were encouraged to respond as
personally as possible, and to reﬂect on and discuss what they
would do as (grand-) parents in the context of their speciﬁc
(grand-) children. The parents were asked what they personally
would like to be told; those without children were asked what
they thought they would like to be told if they were parents; and
the grandparents were asked what they thought their children
should be told about their grandchildren.
2. Methods
The aim of the focus group discussions was to provide a broad
sketch of concerns and ideas around the communication of sec-
ondary variants from next-generation sequencing technologies
involving children. Ethics committee approval was sought and
obtained from the medical ethics committee of the University
Hospitals Leuven (study number S54646). Recruitment was con-
ducted through designating one or two contact people per target
population. We aimed for between ﬁve and eight participants per
group [Hydén and Bülow, 2003; Kitzinger, 1995]. A range of
stakeholders was recruited (Table 1): participants with (grand-)
children of various ages and those without children; participants
involved professionally with genetics and those who were not;discussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
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EJMG3016_proof ■ 3 February 2015 ■ 3/9and participants with a range of ages. Purposive sampling was
used; this ensures the recruitment of those who have something
to say and are willing to talk to each other because they share
certain characteristics in common [Hydén and Bülow, 2003;
Rabiee, 2004]. Participants received an invitation letter, an
information brochure, and a reminder email or phone call before
the scheduled focus group discussion, refreshments during the
discussion, and a small token of appreciation (a university coffee
mug) at the end. Participation in the discussion was understood
as implicit consent to the research.
An hour was allotted to each focus group, and a moderator (GC)
and observer were always present. A location and time was chosen
that best suited the participants. Two of the focus groups were
conducted in English (immigrant parents and genetics PhD stu-
dents) and the remaining six in Dutch. Citations below have been
translated into English when necessary. The English version of the
discussion guide is reproduced in Online Supplementary Material
S1. A relatively structured format for the discussions was favoured
to facilitate the consistency of data collection [Morrison-Beedy
et al., 2001]. At the same time, the moderator and observer
restricted their interventions, to ensure that it was the
participants leading the conversation amongst themselves
according to what they perceived to be important [Smithson,
2000]. Participants were assured in writing in an information
brochure and orally at the start of a focus group discussion that
all results would remain conﬁdential, and that their participation
would have no possible effect on their interactions with the
university hospital. At the end of the discussion, participants
were asked to ﬁll out a socio-demographic form, including the
number and ages of their (grand-) children andwhether or not they
were familiar with genetic diseases (speciﬁcally, whether they
were familiar with genetic diseases in their family, through their
studies, and/or through their work).
Three scenarios were presented to participants (time permit-
ting). The ﬁrst two scenarios involved a range of secondary variants
found in the participant’s (grand-) child (or their hypothetical child,
where relevant) presenting at a genetics clinic with a suspected
genetic condition (Scenario 1), or found in themselves (Scenario 2).
The third scenario involved the same secondary variants but as the
primary target of genetic testing. As this scenario was only dis-
cussed by three groups, and the discussion usually revolved around
what the participants wanted to know about themselves rather
than their children, results from scenario three were ultimately
omitted from the analysis. As in a previous study [Christenhusz
et al., 2014], the word “unexpected result” was used with
participants. “Unexpected result” is a term that could be easily
understood by participants and is easy to translate into Dutch
without sounding overly technical, although this is not our
preferred term in professional discussions [Christenhusz et al.,
2013a]. The “unexpected results” were contrasted with the
“expected result,” a diagnosis or explanation for the child’s
suspected genetic condition. Participants were presented with
short descriptions of seven (eight in scenario 2) possible
”unexpected results,” and asked in pairs to arrange the variants in
terms of what they deﬁnitely did or did not want disclosed, and
what they felt ambivalent about. This almost pedagogical method
of running the discussion guaranteed a common communicative
ground, which was helpful because most of the participants had
no direct experience with the topic of secondary variants arising
from next-generation sequencing technologies [Hydén and
Bülow, 2003]. It also made it easier for participants to focus their
comments on each other rather than the moderator, as they
sought to explain their choices to each other [Kitzinger, 1995].
Moreover, by giving everyone a chance to ﬁrst organise their
thoughts around something concretely in pairs, those who werePlease cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doislower verbalisers were not disadvantaged. Examples had been
chosen based on our two literature reviews and a method for
categorising secondary variants developed by Berg et al. [Berg
et al., 2011; Christenhusz et al., 2013b, 2013c]. Examples differed
in terms of severity, treatability, time of onset, level of risk,
carrier status, stigmatisation potential, and health relevance.
These factors served as a starting point for the ensuing
discussions on why participants had placed the secondary
variants where they had.
Transcripts of the discussions were analysed using NVivo 9
software and content and narrative analysis methodologies [Hsieh
and Shannon, 2005; Riessman, 2005; Smith, 2000]. While content
analysis focuses on speciﬁc characteristics of the data, narrative
analysis takes a more holistic view, focussing more on context
and perspective [Smith, 2000]. These complementary modes of
analysis are very well-suited to the methodology of focus group
discussions, in which participants develop their opinions together,
synergistically [Smithson, 2000]. Codes were developed by the
moderator (GC) and subsequently agreed upon with two co-
authors (KDV, KD). The analysis focussed on statements made by
participants regarding what they would personally expect, desire
or decide as a parent. In particular, whenever a participant stated
that their personal and professional views conﬂicted regarding the
disclosure of a particular secondary variant, the conﬂict was noted
and only the participant’s personal view was included in the
analysis.
3. Results
3.1. Study population
A total of 50 individuals participated in eight exploratory focus
groups between October 2012 and May 2013 (Table 1). Twenty
seven were parents, six were grandparents, and seventeen had no
children. An additional 7% failed to turn up when expected,
although this only occurred with three groups. Groups consisted
of an average of six participants, being mixtures of acquaintances
(colleagues, friends and/or occasionally family members) and
strangers. Given the potentially wide-ranging scope of the topic,
this proved to be the ideal number to ensure that all participants
had a chance to share all they wanted to say within the one hour
time limit. The focus of our gatherings was sufﬁciently clear that
strangers were able to talk easily with each other, and sufﬁciently
novel that acquaintances did not start talking off-topic. Approxi-
mately 25% were non-Belgian, spread across half of the groups
(most of course in the group which speciﬁcally recruited immi-
grants). Some expressed no familiarity with genetic diseases either
through family history, studies or work; however, this was never
more than half of the group (Table 1). A range of ages for
participants and their children were represented. Women usually
outnumbered men, though never markedly. One group (of bio-
informaticians) coincidentally consisted of only men. No differ-
ences were noticed between genders, except in discussions on a
secondary variant of the father’s infertility (implying misattributed
paternity).
3.2. General ﬁndings
After a brief introduction to each scenario, focus group partici-
pants were asked in pairs to arrange examples of secondary vari-
ants (heart arrhythmia, breast cancer, carrier of cystic ﬁbrosis,
increased risk of type 2 diabetes, Huntington’s disease, higher
percentage of Neanderthal DNA, late-onset Alzheimer’s disease,
and male infertility) according to those which they deﬁnitely
wanted to know, those which they deﬁnitely did not want to know,discussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
Table 2
Disclosure themes raised for discussion, grouped around three types of factors:
factors related to the speciﬁc characteristics of the secondary variant; factors related
to the parents and child-patient; and factors related to the broader context.
Speciﬁc characteristics
of the secondary
variant
Actionability
Life-threatening/life-saving
Timing
Certainty/risk
Parents and
child-patient
Responsibility of parents
Rights of parents vs. rights of children
Privileged relationship of parents
(Potential) guilt
Identity questions
Broader contextual
factors
Role of the clinical geneticist or doctor
Wider family
Broader philosophical convictions
(regarding secondary variants as information;
relative importance of genetic information;
concern with genetic advances)
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EJMG3016_proof ■ 3 February 2015 ■ 4/9and those which they did not mind if they knew or not. The
arrangement of examples served as a springboard for discussions
on what motivated participants in their disclosure preferences.
Participants often changed the position of particular examples in
the course of a scenario, due to the arguments of others or their
own changing arguments. As a result of this changeability, and
because we are more interested in participants’ arguments and
motivations than their mere disclosure preferences, we have not
included a ﬁgure showing the disclosure preferences of each focus
group. In general, more participants were in favour of the disclosure
of secondary variants such as heart arrhythmia and breast cancer,
than the disclosure of late-onset Alzheimer’s disease. No clear
pattern of support for or opposition to disclosure could be dis-
cerned for the other examples of secondary variants. All groups
were split on the disclosure of the father’s infertility. Male re-
spondents reacted more personally to this secondary variant
example than female respondents did, although some men then
argued in favour of disclosure while others argued against it.
On occasion, participants noted that they would respond
differently depending on their role. Some said they would like to
know more about themselves than about their (hypothetical)
children, some less. One PhD student (PhD student 4, male, no
children) said he would like to knowmore if he were a parent than
he would be willing to disclose as a doctor. In contrast, one clinical
geneticist (clinical geneticist 5, female, two children under 5) said
that she would like to know less as a parent than what they had
agreed upon as a department that parents should be told. The re-
sults that follow deal only with what parents said in their role as
parents (or students or grandparents said about parents). The
tension in roles will be returned to in the discussion.
At one point in the focus group discussion involving parents of
teenagers and young adults, one of the participants (parent of
teenagers and young adults 5, male, two children over 13)
expressedwith a little frustration, “It’s just all so arbitrary, it’s so, so,
unbelievably person-dependent and situation-dependent . and
disease-dependent too, I don’t know.” This is actually a useful and
succinct way of dividing the types of arguments that surfaced in
discussing the return of secondary variants. Rearranging the three
types of factors shows a gradual broadening of focus, from speciﬁc
characteristics of the secondary variant itself (disease-dependent
factors) through the main actors directly affected by disclosure (the
parents and their child who is the patient, falling under person-
dependent factors) to contextual factors broader than the parents
and child (situation dependent factors). We present below argu-
ments and motivations arranged according to these three themes
related to secondary variants in general (summarised in Table 2);
Online Supplementary Table T1 displays those arguments that
were more speciﬁc to each of the eight secondary variants
presented to participants.
3.3. Factors related to the speciﬁc characteristics of the secondary
variant
The actionability of a secondary variant was a major topic of
discussion, which included the possibilities of treatment, preven-
tion strategies such as screening or behavioural changes, and pre-
natal options. The seriousness of the recommended treatment and
how easy the condition would be to control once parents knew
about it were also raised as factors; that is, conditions that would
require more serious or risky treatments or that would be more
difﬁcult to control, were more likely to be classiﬁed by participants
as “do not disclose.”
There was almost universal agreement across all groups that
life-threatening conditions be disclosed to parents, especially if the
information would prove to be life-saving because the conditionPlease cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doionce known could be treated or prevented. However, some par-
ticipants could envision reasonswhy theymay notwant to knowall
life-threatening conditions. One parent of young children (parent of
young children 1, male, two children under 5 and one under 13)
distinguished between life-threatening conditions in which the
predicted progression would be slow and drawn-out (which he did
not want to know) and those inwhich the predicted onset would be
sudden (which he did want to know, to have the chance to say
goodbye). Two parents of teenagers and young adults expressed
doubt about the usefulness of knowing life-threatening conditions,
arguing that it is of course impossible to know exactly when the
crisis might hit (Online Supplementary Table T1, heart arrhythmia
example). One of these mothers (parent of teenagers and young
adults 3, female, three children over 18) talked about a similar
experience when her daughter had her ﬁrst epileptic ﬁt and their
“world stood still”; no one in the family knew of the risk in
advance. As this participant continued to compare the
hypothetical example of heart arrhythmia with her personal
experience with a daughter with epilepsy, she became
increasingly unsure of whether she would want to know such a
ﬁnding in advance or not. Ultimately, assisted by the input of
another participant, this participant concluded that a major
reason favouring disclosure would be the availability of effective
preventive measures, which was assumed to be the case for heart
arrhythmia but not for epilepsy:
But imagine that you had known about it [epilepsy] beforehand, it
was still going to happen, probably, wasn’t it? (parent of teenagers
and young adults 5, male, two children over 13)
Yes, probably, yes (parent of teenagers and young adults 3, fe-
male, three children over 18)
Yeah because there’s no preventive medication you can take in
advance, I assume? (parent of teenagers and young adults 5)
This example illustrates how participants drew on their own
experiences to develop their arguments, and how this happened as
a process with input from other participants.
The importance of timing was discussed in a range of ways. For
example, some discussed the relevance of when the ﬁnding would
manifest. Therewere arguments in favour of the disclosure of early-
onset conditions such as heart arrhythmia and against the disclo-
sure of late-onset conditions such as Huntington’s disease and late-
onset Alzheimer’s disease. At the same time, some made a
distinction based on when the life of the child would be impacted
by the condition, rather than when the child would start to showdiscussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
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EJMG3016_proof ■ 3 February 2015 ■ 5/9symptoms of the condition. Such participants characterised con-
ditions like breast cancer or Huntington’s disease as “early-impact,”
because even though the child would not develop these conditions
during childhood they would be impacted during childhood if their
parent got sick and the genetic cause was unknown. Participants
who made such a distinction argued that so-called “early-impact”
conditions should be disclosed to parents, contrasting these con-
ditions with “late-impact” conditions like (late-onset) Alzheimer’s
disease which would appear after the children had reached ma-
jority and which therefore did not need to be disclosed during
childhood. Some participants wondered if the secondary variant
could just sit in the medical ﬁle until it became relevant or vital.
Disclosure only once symptoms started appearing could provide a
reassurance of what was happening, and lead to a timely diagnosis.
Others cast doubt on the practicality of this suggestion by pointing
out that it is difﬁcult to correctly diagnose certain conditions such
as Huntington’s disease or Alzheimer’s disease in the early stages,
and so it may be difﬁcult to know when “relevant” is. In addition, it
might be difﬁcult to know when the time is ripe to tell the child.
Some expressed hope that what is now not actionable may become
so in the future; there was then debate about whether the medical
ﬁle and/or doctors, or parents themselves, were the best keepers of
such information on behalf of the child. The importance of being
“on time” with treatment and prevention was weighed against the
intervening years of worried vigilance. Some argued that they could
just wait until symptoms started appearing.
The certainty of the ﬁndingwas discussed in various ways, and it
was sometimes difﬁcult to knowwhat participants precisely meant
with this term. Sometimes this referred to the reliability of the
genetic test and the certainty of the doctor about the ﬁnding. At
other times this referred to the predictive value of the ﬁnding, and
how certain one could be about the time and mode of onset, pro-
gression, and clinical manifestation range of the condition. It was
not always clear whether participants understood the distinctions
between reliability of the test and predictive value of the ﬁnding;
for example:
. but if for example ah Alzheimer’s disease, if you say that that is
only 50-50%, then no thank you, don’t tell me. We wouldn’t like to
know. I don’t know with you, is that 50-50 for you? (immigrant
parent 7, female, two children under 5 and one child over 13)
yeah (immigrant parent 6, female, one child under 5)
if they say that the test is only 50% correct (immigrant parent 7)
mmm (immigrant parent 6)
so 50% chance that you don’t have this problem, would you still
like to know? (immigrant parent 7)
no (immigrant parent 6)
This highlights the importance of clarifying what parents and
medical professionals mean bywords like “correct” and “chance” in
genetic consultations. The idea of certainty was also linked to that
of risk, as seen in the excerpt above, though therewas no consensus
as to how high a risk should be to be judged worth reporting, or
what doctors should do about large ranges of risk. Some wished to
know risks “just in case.” Others spoke about the potential mean-
inglessness of statistics, and the complexity of interpretation
brought about by additional environmental and lifestyle factors.126
127
128
129
1303.4. Factors related to the parents and child-patient
Particular ideas about the parents and the child who was the
patient often inﬂuenced discussions, speciﬁcally the relationshipPlease cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doibetween parents and children and their respective roles. One
central ideawas the responsibility of parents. This was translated in
various ways: parents should know about early-onset secondary
variants, because at that time of life they are still responsible for
their children; parents are responsible to learn about treatable or
preventable conditions and then act accordingly; parents are
responsible to store late(r)-onset secondary variants on behalf of
their child. Regarding the latter, some argued that as long as
someone took responsibility to make sure the child received the
information when they wanted it, it did not matter if this were
someone other than the parent.
Discussions about rights could go in two directions: the rights of
parents to know and then make choices, which for some included
the choice not to tell the child if the parents thought this best; and
the right of the child not to know or not to have their parents know,
coupled with the idea that people have more right to know
something about themselves than about their children. One
grandfather (grandparent 1, male, four grandchildren of various
ages and two children) argued passionately that genetic informa-
tion was the “personal passport” of the child and should be kept
private. Some felt that the doctor did not have the right to say they
would not disclose. This was related to the sentiment that it was not
right for someone else to know something about the child that the
parents did not know, whether that be misattributed paternity or
any of the other examples.
The privileged relationship of parents to their children was
discussed in several ways. Several participants without children
from the groups of bio-informaticians and PhD students suggested
that because the parents know their child best, they should stand
central in disclosure decisions. One participant explained that it is
in the best interests of the child that the parents know and can
decide, especially in the context of ambiguous information that
may not be immediately relevant:
Yeah I would, I think I’m adult enough and I understand enough
about the technology to see, yeah, what it’s worth, and then it’s up
to [us as] parents to decide, to communicate, what we’ll do with it.
But I do think it’s up to us because we completely, we know our
children a lot better and we [have] a lot more information than
anyone else. So I think for the child that it’s, that it’s best that all the
information be centralised because otherwise . (bio-informa-
tician 4, male, without children)
However, there was concern in these and other focus groups
that knowing might harm the parent-child relationship, by making
the parent’s role more difﬁcult or by negatively inﬂuencing either
the parent’s or the child’s behaviour. One mother of teenagers
(parent of teenagers and young adults 2, female, two children over
13) argued that parents have enough choices to make anyway. It
was acknowledged that all parents are different, and that disclosure
of secondary variantsmay not be a good idea to parentsmore prone
to worrying or being over-bearing, or those not able to handle the
information. Some grandparents and students queried why the
parents should be told ﬁrst.
Two ﬁnal factors related speciﬁcally to parents and children
were raised in the focus groups. Discussions about guilt could go in
two ways: guilt if the parent could have known and chose not to,
and the guilt in knowing that you passed it on to your child (or
grandchild). There was concern that guilt might in turn harm the
couple’s relationship (i.e. the relationship between the parents of
the child). Finally, there were concerns amongst parents of teen-
agers that disclosure of secondary variants to the child or even the
young adult (over the age of 18) might raise identity questions for
them; that is, they might have difﬁculty incorporating thediscussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
G.M. Christenhusz et al. / European Journal of Medical Genetics xxx (2015) 1e96
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
EJMG3016_proof ■ 3 February 2015 ■ 6/9knowledge of the secondary variant into their identity as a person
with certain ﬁxed expectations about their present and future
health.69
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1303.5. Factors related to the broader context
The broader contextual factors raised for discussion can be
further divided into three groups: the clinical geneticist or doctor,
the wider family, and broader philosophical convictions. Included
in the former were discussions on the role of the doctor. Note that
“the doctor” was used for various medical professionals without
distinction, including clinical geneticists and general practitioners
(GPs). As mentioned above, some felt that if someone else, such as
the doctor, knew a certain secondary variant, then they as the
parent should know too. The doctor was seen as having a re-
sponsibility or duty to disclose actionable ﬁndings; one grand-
mother (grandparent 4, female, four grandchildren of various ages
and one child) declared: “I would ﬁnd it criminal if they didn’t do
that!” Others argued that it would be difﬁcult to devise standard
disclosure guidelines that took into account differences between
doctors with different levels of expertise and knowledge. The idea
that the doctor should just focus on “doing medicine” was used as
an argument in four groups (the two student groups, parents of
teenagers and young adults, and grandparents) against the speciﬁc
disclosure of results such as a higher percentage of Neanderthal
DNA or misattributed paternity. A similar sentiment was expressed
by those who queried the need in general for broad genetic tests,
wondering if this would indeed mark an improvement in medical
practice.
Related to views on the role of the doctor, the three focus groups
not composed of parents (grandparents, biomedical sciences mas-
ter students, and genetics PhD students) were each asked specif-
ically if they thought parents should ever be forced to accept
disclosure of a secondary variant against their will. All three of
these groups showed wide-spread support for doctors always
disclosing information regarding a potentially life-threatening
condition such as heart arrhythmia. Reasons given included the
importance of knowing so as to start treatment or screening at an
early age, the fact that it was someone else’s life (i.e. the child’s, not
the parents’), and the responsibility or duty of the doctor towards
the child. One grandmother (grandparent 6, female, three grand-
children under 13 and two children) suggested that parents who
were against the disclosure of all secondary variants would prob-
ably not ask for genetic testing in the ﬁrst place. However, if parents
did opt for genetic testing while opposing the disclosure of some or
all secondary variants, this grandmother expressed discomfort at
the idea of making certain types of disclosure compulsory for
parents; she felt that ﬁnal responsibility lay with the parents, not
the doctor. One grandfather (grandparent 1, male, four grand-
children of various ages and two children) responded by proposing
that the doctor should be allowed to evaluate the situation and the
desirableness or timeliness of disclosure, but that in general the
doctor should disclose such information:
But I think in that case, ah then I assume that the doctor, and
certainly the GP, is pretty well situated to then look at the situation
and the family ah. he can evaluate it and see what.what would
be best for him to do in that case, and he decides that there must,
yeah he makes the decision himself, whether he says it or not
(grandparent 1, male, four grandchildren of various ages and
two children)
Yes, exactly (grandparent 6, female, three grandchildren under
13 and two children, critical towards compulsory disclosure)
And he has to evaluate it (grandparent 1)Please cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doiMmmm yes (grandparent 3, female, four grandchildren under 13
and two children)
Eh? You can come across situations in a family where it’s not
appropriate. (grandparent 1)
In terms of the rest of the family, some described having a family
as an incentive to want to know, to then make decisions of beneﬁt
to the family; many were open to sharing the information with the
wider family. Having a family history of a particular condition, such
as type 2 diabetes or Alzheimer’s disease, was used to argue both
for and against disclosure. A negative family experience with a
particular condition made some participants more and some less
likely to want to know their risk of that condition. Some members
of the focus group of bio-informaticians argued strongly that family
history and other health parameters were better predictors of
complex, common conditions than genetic makeup. These partici-
pants consequently tended towards ambivalence or opposition to
disclosure of these types of conditions, and showed more interest
in de novomutations related to less complex conditions. Two other
factors related to the wider family which were used to argue
against disclosure were a possible negative inﬂuence on the fam-
ily’s behaviour if the secondary variant were disclosed, and the
concern that the timing may not be right in the family.
Finally, broader philosophical convictions surfaced in all of the
focus group discussions, underlying participants’ natural prefer-
ences for or against disclosure. These convictions formed part of the
context inﬂuencing disclosure. For instance, there were those who
emphasised the informational content of disclosure. They were
happy to receive secondary variants to add to all the other pieces of
health-related information. Theywould often also highlight the gap
between knowing something and acting on it. Some saw the pos-
sibility of tension arising if parents wished to act on a certain piece
of information without knowing whether their children might
want to know that information. For example, the clinical genetics
centre staff members discussed the dilemma of wanting to know
and act on a treatable secondary variant such as a BRCA mutation
that would be relevant to them as a parent, while still safeguarding
their child’s future autonomy and right not to know.
A second philosophical standpoint was defended by those who
acknowledged that genetic information might in some cases be
useful, but whose focus was elsewhere. These participants rela-
tivised the importance of genetic information. They did not have to
know or measure or weigh everything in general, and were happy
to just keep living as they were, healthy and in happy genetic
ignorance. Some argued that wanting to know and control every-
thing goes against the philosophy of having children. They argued
that not everything can or should be controlled, in contrast to other
participants who favoured disclosure of certain variants to give
them control over the situation. One master’s student (master’s
student 3, male, no children) passionately argued that all this new
genetic knowledge might be a great improvement for science but
not for humanity, because knowing all the slight increases and
decreases in personal genetic risk will not make us happier.
In contrast to those who brushed off secondary variants as just
information were those gravely concerned about the implications
of disclosure, particularly if this became standard. Some were
worried about the storage and appropriate release of the data, for
example release to insurance companies or to the future unsus-
pecting adult child. One PhD student (PhD student 7, female, no
children) spoke of the information as a “time-bomb,” so that it was
better that no one should know. While some wanted to know even
if it would be difﬁcult to hear, others spoke of the burden of
knowing. A few were anxious that knowing and worrying about it
might hasten the onset of certain conditions. There were alsodiscussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
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EJMG3016_proof ■ 3 February 2015 ■ 7/9concerns amongst some groups not professionally involved in ge-
netics about where to draw the line with genetic information, and
about the kind of society that might result from widespread use of
next-generation sequencing technologies. As mentioned earlier,
some queried the need for genetic sequencing techniques such as
WGS in general. One of the parents of teenagers and young adults
(parent of teenagers and young adults 2, female, two children over
13) was categorical in her opposition to the disclosure of all sec-
ondary variants, favouring a relationship with her child that would
be as free as possible from unnecessary worry over the knowledge
of what she characterised as “only risks.”
4. Discussion
The sketch of concerns and ideas around the communication of
secondary variants from next-generation sequencing technologies
provided by the eight focus group discussions proved much
broader than earlier recommendations on the topic [Christenhusz
et al., 2013b]. For example, one of the earliest recommendations
focused on likely life-threatening and grave conditions that could
be avoided or ameliorated [Wolf et al., 2008]. As explained above,
we chose the examples of secondary variants used to spark
discussion based on these and other factors highlighted in the
literature: alongside severity and treatability were the time of
onset, level of risk, carrier status, stigmatisation potential, and
medical applicability. Our results show both that focus group
participants were also interested in other factors such as those
involving the parent-child relationship and the broader context
(Table 2), and that they would on occasion use the same factors to
argue opposing positions. This reafﬁrms the need for counselling
and other forms of dialogue over categories and checklists, to try
and uncover which motivations weigh most strongly with
parents or patients in speciﬁc contexts [Christenhusz et al.,
2013c]. Categories and checklists composed by medical
professionals may not reﬂect the values of parents and patients.
At the same time, it will be difﬁcult to distil the variety of
parental and patient values into categories or checklists that can
be universally applied. Moreover, most of our research
participants could acknowledge the value of arguments
supporting both the disclosure and the nondisclosure of most
types of secondary variants, meaning that they would accept the
disclosure and nondisclosure of most types of secondary variants
if this were justiﬁed by arguments. Our results thus support a
recommendation for more dialogue between medical
professionals and parents or patients before disclosure decisions
are made. Many practical questions regarding such dialogues will
need to be investigated, such as who should be responsible for
leading the discussions, how long they will take, who pays, and
how such discussions might be regulated, documented and
followed up. The results of empirical ethical research such as the
present study can aid in the process of answering such questions.
In terms of minors in particular, the ethical and empirical
literature often focus on two points [Christenhusz et al., 2013b,
2013c]. Firstly, the literature advises that more caution should be
exercised in the disclosure of incidental ﬁndings involving
children than involving adults; as a result, usually only the
disclosure of life-threatening or grave ﬁndings with proven treat-
ability or prevention options is approved. Cases of unlikely net
beneﬁt which would usually be left to the discretion of adults are
not advised to be disclosed if children are involved [Christenhusz
et al., 2013b]. Secondly, in cases of conﬂict between the rights
and best interests of parents and children, the literature usually
sides without much hesitation with the children. The results of
our focus groups and empirical research of others set these two
points against a larger backdrop. Results from focus groups withPlease cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doipublic stakeholders conducted by Driessnack et al., in contrast to
their focus groups with professional stakeholders, echo some of
our ﬁndings of an openness to the ambiguity of life and the
importance of the privileged relationship between parents and
children [Driessnack et al., 2013]. This implies a more integrated
view of the potential impact of a given ﬁnding on the family as a
whole than a careful tallying of the net beneﬁts and risks for the
child. In 2013, the American College of Genetics and Genomics
(ACMG) published recommendations that veriﬁable, medically
actionable ﬁndings on their list of secondary variants be sought
for and disclosed, regardless of whether the patient is an adult or
a child [Green et al., 2013]. They defend this stance by citing a
family-wide view of disclosure [Evans, 2013], similar to that
displayed by our participants. That is, their argument for
disclosure is that any potential clinical beneﬁt to the child’s
family will also be of indirect immediate beneﬁt to the child. At
the same time, our focus group results would not support
compulsory disclosure of all secondary variants agreed upon by
medical professionals. A more integrated, family-wide view of
disclosure suggests the need for a slight re-phrasing of the general
recommendation that parents not be given the option to refuse
disclosure of serious, treatable, early-onset conditions on behalf of
their children [Hens et al., 2011; Wolf et al., 2008]. While only three
of our ﬁfty participants called this stance into question, their
responses suggest that parents may occasionally have good
reason for refusing disclosure at a speciﬁc time, although as other
participants suggested, such parents would probably not opt for
genetic testing at that time anyway.
We observed that the presence of a child, and more speciﬁcally
the participant’s child, in the disclosure equation inﬂuenced par-
ticipants’ arguments; as stated above, some participants noted that
they would want to know more (and some less) about themselves
than their child, and occasionally experts stated that they would be
less (or more) likely towant to disclose something if it was a patient
than their own child. However, as was also the case when examples
of family history were incorporated as arguments, acknowledging
that the child focus would inﬂuence the decisionwas not enough to
then predict what this decision would be. Family history is seen by
some authors, and repeated by some of our participants, as an
argument favouring predictive genetic testing of children after
appropriate genetic counselling if families speciﬁcally request it
[Robertson and Savelescu, 2001]. However, other focus group
participants used their family history as a reason to not want to
know certain secondary variants. The Family Illness Paradigms
model may prove helpful here [Rolland, 1987]. The model
emphasises the importance of the family’s health locus of control
(internal or external), their multigenerational experiences with
illness and loss, ethnic and cultural background, and assumptions
about disease causation on how the family responds to illness. A
family’s particular illness paradigm could help predict how they
might cope as a family with various secondary variants found in
their child. This is not to suggest that the illness paradigm should
determine what does and does not get disclosed; rather, that it
can provide clues as to possible issues that might arise if
disclosure or non-disclosure is decided upon. For example, ima-
gine that a BRCA1 mutation were found as a secondary variant.
Imagine ﬁrstly that a family’s experiences with illness have led
them to conclude that they have no control over the progression of
disease, and that developing a disease is a matter of bad luck or
personal guilt. Based on this family illness paradigm, it would be
advisable to emphasise during the disclosure of the secondary
variant that there are certain prevention techniques available, so
that this secondary variant is not automatically received fatalisti-
cally by the family. Secondly, imagine another family whose ex-
periences with illness have led them to conclude that with the rightdiscussions on secondary variants and next-generation sequencing
.org/10.1016/j.ejmg.2015.01.007
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EJMG3016_proof ■ 3 February 2015 ■ 8/9attitude, medication and lifestyle diseases can be kept under con-
trol. Based on this second family illness paradigm, it would be
advisable to emphasise during the disclosure of the secondary
variant that not all genetic variants associated with an increased
risk of breast and ovarian cancer are currently known, and that not
all incidences of cancer have a genetic component.
The potential impact of one’s family illness paradigm could
possibly account for why the results we obtained from interviews
with parents whose children had undergone array-CGH testing
weremore uniform than thewide range of views expressed in focus
groups [Christenhusz et al., 2014]. Interview parents formed amore
homogeneous group than focus group participants, as they all
reported similar stories of long searches for a diagnosis,
continuing uncertainty, and loneliness, against a supportive
background of (at least one side of the) extended family and
clinical genetics staff. In general, participants in both interviews
and focus group discussions were conscious of the effect that
their unique experiences had on their disclosure preferences, and
used these experiences as authoritative arguments. Given the
central role of experience in forming preferences and values
[Kuczewski, 1996], due weight should be given to patient and
family experiences with illness in disclosure discussions.
The relevance of the exact timing and progression of a given
genetic condition is often minimised when secondary variants are
divided into child-onset and adult-onset conditions, with the cor-
responding recommendations for disclosure. Some participants
afﬁrmed the importance of the time of onset, linking this to pro-
tecting the child’s right to choose to be tested as an adult and the
child’s right to privacy. Not respecting these rights can border on
instrumentalising the child for the sake of the parents. At the same
time, other participants pointed to the importance of the time of
impact rather than the time of onset. Illness in the family, whether
of the child themselves or their parents, will impact the child while
they are growing up. The Family System Genetic Illness model, an
adaptation of the Family Illness Paradigms model, emphasises the
dimension of time alongside other key genetic disease variables
[Rolland andWilliams, 2005]. Themodel highlights the signiﬁcance
of various milestones such as starting a family, work life and
retirement when reﬂecting on the impact of genetic disease.
Attention is also paid to the nonsymptomatic time phases of pre-
and post-testing. Because of the variation in the medical and psy-
chosocial demands made on individuals (including children) and
the family as awhole across the course of the disease, not all “adult-
onset diseases” should be treated the same when considering
disclosure of secondary variants about children.
We found it an enrichment to bring together genetics pro-
fessionals (speciﬁcally, clinical geneticists and bio-informaticians)
in their role as parents. At times they showed a more open atti-
tude to disclosure than has been reported by other professional
groups [Brandt et al., 2013; Green et al., 2012; Hayeems et al., 2011;
Lemke et al., 2013; Levenseller et al., 2013; Lohn et al., 2013;
Townsend et al., 2012]; this might be attributed to the difference
between focussing on the individual and aiming at standard
guidelines for a large group of people. This begs the question of
whether guidelines might beneﬁt not just from the input of a
range of stakeholders but also from professionals thinking
outside of their usual role.
Possible limitations include the absence of certain stakeholders.
In particular, it is unfortunate that our attempts to recruit patient
group representatives, paediatric nurses, and parents of ill and
disabled children, failed to achieve enough participants. The views
of parents of children with learning difﬁculties or mental disabil-
ities would have been especially enriching, as many of the children
who undergo genetic testing fall under this category, and the extent
to which these children will be able to make fully independentPlease cite this article in press as: Christenhusz GM, et al., Focus group
technologies, European Journal of Medical Genetics (2015), http://dx.doidecisions once they reach adulthood can be uncertain. We sug-
gested in a previous study that the ability of parents to imagine
independent grownup children may affect the parents’ disclosure
preferences, and that this deserves further investigation
[Christenhusz et al., 2014]. A complementary study should also
include the views of children on their motivations surrounding
disclosure. Furthermore, as WGS and WES become more a part of
routine clinical genetics practice, retrospective studies should be
done with those who have had direct experience with these new
technologies, including direct experience with secondary variant
disclosure discussions. As was pointed out by some of the
genetics professionals who participated, it may have been better
if we had emphasised more the risk and therefore uncertain
nature of genetic information; in so doing, we may have
inadvertently partially contributed to the misconception that
genetics is 100% predictive. It would have been interesting to
include psychiatric conditions. All participants live in a single
province of Belgium; care should be taken in extrapolating results
internationally. Future research could investigate possible impacts
on disclosure preferences caused by cultural and religious
differences. At the same time, research involving a broader
spectrum of stakeholders should refrain from relying too heavily
on correlating categories of people with disclosure preferences.
As our results suggest, how someone experiences and interprets
their life can shed more light on their stated disclosure
preferences than a collection of facts and experiences. In line
with this ﬁnding, further research is needed to explore the
impact of the Family Illness Paradigms Model on disclosure
preferences and to then translate this into practice.Conﬂict of interest statement
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